Leukemia

Adults with acute myeloid leukemia with IDH mutations appeared to be at increased risk for coronary artery disease and exacerbated cardiotoxicity during treatment with anthracyclines, according to study results.

Black young adults with favorable molecular-risk acute myeloid leukemia had poorer survival outcomes than their white counterparts, according to study results presented at the virtual ASH Annual Meeting and Exposition.

Discontinuation of tyrosine kinase inhibitors after 3 years of use appeared safe for adults with chronic myeloid leukemia who achieved a sustained deep molecular response, according to results of the LAST study published in JAMA Oncology.

Recombinant human granulocyte colony-stimulating factor combined with minimal-dose decitabine appeared to reduce relapse incidence after allogeneic transplant among patients with high-risk acute myeloid leukemia, study results showed.

The University of Texas MD Anderson named 10 early-career faculty members to its fifth annual class of Andrew Sabin Family Fellows.

Ten years ago, researchers at NCI reported use of CD19-directed chimeric antigen receptor T-cell therapy that successfully induced remission in a patient with follicular lymphoma.

A four-factor prognostic model identified patients with chronic lymphocytic leukemia who had poorer survival outcomes with ibrutinib, according to study results published in Journal of Clinical Oncology.

So-called “chemo brain” is a functionally limiting and frustrating consequence of curative treatment for cancer.

ASH announced the election of four new members to its executive committee.

A combination of obinutuzumab, ibrutinib and venetoclax induced deep remissions in patients with treatment-naive or relapsed/refractory chronic lymphocytic leukemia, according to study results published in Journal of Clinical Oncology.